Trial reportHaematologica2013
Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.
Trial report in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Iron chelation of hetrombopag in aplastic anemia: a post hoc analysis of a phase II study.Annals of hematology · 2022Trial
- [Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Trial
- Longitudinal clinical and preclinical studies identify hetrombopag as a potent chelator for systemic iron overload.HemaSphere · 2026Article
- Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes.Blood advances · 2022Article
- Long-term eltrombopag for bone marrow failure depletes iron.American journal of hematology · 2022Article
- From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox.Frontiers in oncology · 2021Review
- Very long-term follow-up of aplastic anemia treated with immunosuppressive therapy or allogeneic hematopoietic cell transplantation.Annals of hematology · 2020Article
- Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation.Therapeutic advances in hematology · 2020Article
- Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation.Therapeutic advances in hematology · 2020Review
- [Research progress of characteristics and mechanisms of iron overload affecting bone marrow hematopoiesis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Deferasirox in thalassemia: a comparative study between an innovator drug and its copy among a sample of Iraqi patients.Therapeutic advances in drug safety · 2019Article
- Activity of eltrombopag in severe aplastic anemia.Hematology. American Society of Hematology. Education Program · 2018Review
- Activity of eltrombopag in severe aplastic anemia.Blood advances · 2018Review
- Essential role of FBXL5-mediated cellular iron homeostasis in maintenance of hematopoietic stem cells.Nature communications · 2017Article
- Myelodysplastic Syndromes and Iron Chelation Therapy.Mediterranean journal of hematology and infectious diseases · 2017Review
- [Effects of pre-immunosupressive therapy iron overload on hematologic response of severe aplastic anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- [Advances in the treatment of severe aplastic anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.Drug design, development and therapy · 2015Review
- Recent advances in treatment of aplastic anemia.The Korean journal of internal medicine · 2014Review
- Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.Mediterranean journal of hematology and infectious diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reports are emerging of hematologic responses associated with iron chelation therapy; however, studies are limited in aplastic anemia patients. Deferasirox reduced iron overload in aplastic anemia patients enrolled in the EPIC (Evaluation of Patients' Iron Chelation with Exjade(®)) study (n=116). A post hoc analysis of hematologic responses was conducted on 72 patients with evaluable hematologic parameters (according to UK guideline criteria), 24 of whom received deferasirox without concomitant immunosuppressive treatment. Partial hematologic responses were observed in 11 of 24 (45.8%) patients; all became transfusion-independent. One patient had an additional platelet response and one patient had an additional platelet and hemoglobin response. Mean serum ferritin levels at end of study were significantly reduced in partial hematologic responders (n=11; -3948 ± 4998 ng/mL; baseline 6693 ± 7014 ng/mL; percentage change from baseline -45.7%; P=0.0029). In non-responders, the reduction in serum ferritin was less pronounced (n=13; -2021 ± 3242 ng/mL; baseline 4365 ± 3063 ng/mL; % change from baseline -27.6%; P=0.0171). Alongside reduction in iron overload, deferasirox may, therefore, improve hematologic parameters in a subset of aplastic anemia patients. Further investigation is required to elucidate the mechanisms involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.